







DIFAEM-EPN Minilab Network News 1 / 2022

March 2022

Dear Minilab Network partners,


Today you are receiving the new Minilab Network newsletter comprising the following topics:

- 1. Minilab results 2021
- 2. Recent confirmed cases of falsified and substandard products
- 3. Important information on the remaining project and outlook to successor project
- 4. Spotlight on your activities


Have a pleasant reading.

1. Minilab results 2021

Organization	Conducted Minilab tests
AEST	24
ASSOMESCA	104
CADIMEBU	41
CBC	282
CHAL	13
DCMP	130
FBCMF	258
JMS	52
LIFENET	81
MEDS	12
NKHOMA	15
PCC	102
Gesamtergebnis	1114



Number of medicines without discovered quality problems, substandard and falsified products



Therapeutic categories of analysed samples

These are the next deadlines to hand in your respective test results:

January to March results
April to June results
July to September results
October to December results

hand in until 30st April 2022 hand in until 31st July 2022 hand in until 31st October 2022 hand in until 31st of January 2023









2. Recent confirmed cases of falsified and substandard products

Please note that in all cases batches other than those shown may also be affected.

CHLORO®, CHLOROQUINE PHOSPHATE Tablets BP 250 mg

Stated manufacturer: Leoben Healthcare

Batch: 0432

Mfg. Date: 04/2024Exp. Date: 05/2020

• Result of compendial analysis: no API

• Detected in: Nigeria

 Additional information: "NAFDAC Reg No: 04-4166" stated on the label. The tablets contained in one bulk container showed different embossing.



SA'A QUINE, Chloroquine Phosphate Tablets BP 250 mg

- Stated manufacturer: SA'A Pharmaceutical Products Limited
- Batch: SQ 19043 (on secondary packaging)
- Mfg. Date: 11/2019
- Exp. Date: 10/2022 (on secondary packaging)
- Result of compendial analysis: only 13.1% API
- Detected in: Nigeria
- Additional information: "NAFDAC Reg No: 04– 2855" stated on the label. Different batch numbers and expiry dates were found on the different blisters contained in one box.











QUININE SULPHATE TABLETS B.P. 300mg

Stated manufacturer: WEIDER FARMASOYTSIKE NORWAY

Batch: 8858

Mfg. Date: 02 / 2019Exp. Date: 03 / 2023


• Result of TLC analysis: not API

• Detected in: Cameroon

Additional information: outdated WHO Essential Drugs

Program Logo on the label

In case you discover further (preferably unopened) products with this outdated logo on the label, please inform Difäm immediately (and do NOT open the container).



Zadycine, Azithromycine pour Suspension buvable USP 100mg/5 ml

Stated manufacturer: PRINCEPHARMA

Batch: 06824

Mfg. Date: 02/2020Exp. Date: 01/2023

Result Minilab analysis: reconstitution of the product is not possible

Detected in: DR Congo













PARACETAMOL Tablets B.P 500mg

Stated manufacturer: Gauze

• Batch: 248

Mfg. Date: MAY 2021Exp. Date: APR 2024

 Result of Minilab analysis: tablets do not disintegrate even after several days

Detected in: Nigeria



DEXA-0.4 Dexamethasone Tablets B.P. 0.5mg

• Stated manufacturer: Surmount Laboratories PVT. LTD.


Batch: XD006E

Mfg. Date: not statedExp. Date: 04/23

• Result of compendial analysis: 88% API + 0.2mg methylparabene and 0.1mg propylparabene

• Detected in: Cameroon

 Additional information: The presence of these preservatives in tablets is unusual and unnecessary. Furthermore, the use of propylparabene in children is discouraged, due to possible adverse reactions.













3. Important information on the remaining project and outlook to successor project

As you are probably aware, the current Minilab project (Difam project number 2019-550) funded by Bread for the World will end on 30th June 2022. By this date, also the current MoUs between Difam and the Network DSOs will expire. Difam has already handed in the proposal for a three-year successor project at Bread for the World and we are optimistic that this successor project can start on 1st July 2022 as planned. However, to avoid unnecessary delays in case you are in urgent need for Minilab supplies, please send your list of requirements as soon as possible. We will not be able to process your order during the time of the project's final accounting and until new MoUs have been set up.

A key focus of the foreseen successor project will be to strengthen the cooperation between the Network DSOs and government/state authorities. You may already start developing ideas for cooperative activities with your respective authority, such as advocacy meetings, joint trainings or Minilab demonstrations. We are happy to receive your suggestions.

4. Spotlight on your activities



DCMP, DRC

Sensitation and training on visual inspection was conducted in 30 health facilities in November 2021



ASSOMESCA, CAR

Supervision and training on essential pharmaceutical practice was conducted in three health centers betwen Dec 21 and Jan 22



CHAL, Liberia

A stakeholder meeting together with EPN, the MoH and the LMHRA took place in December 2021 in order to set the framework for future cooperation



CBC & PCC, Cameroon

A joint advocacy meeting with EPN and the Ministry of Public Health took place in March 2022



BUFMAR, Rwanda

A two-days training on medicine quality, QA, QC and the use of the Minilab for **BUFMAR** staff and pharmacists from 14 public hospitals was conducted

Thank you for your efforts and contributions to all achievements of the Minilab network! DIFAEM is looking forward to a further successful collaboration with you!

Kind regards, Christine

C. Hafel - Asal

Gesa

Gesa Gnegel, Pharmacist

Christine Haefele-Abah, Pharmacist, MScIH Head Pharmaceutical Procurement & Projects E-Mail: haefele@difaem.de

Minilab Network Coordinator E-Mail: gnegel@difaem.de

Tel.: +49 7071 / 704 90 13 DIFAEM - German Institute for Medical Mission - Im Rotbad 46, D-72076 Tübingen